Hostname: page-component-74656f9884-rdgjk Total loading time: 0 Render date: 2026-11-08T06:04:18.354Z Has data issue: false hasContentIssue false
  • English
  • Français

Question-and-Answer Session

Published online by Cambridge University Press:  07 November 2014

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

References

REFERENCES

1.Nelson, JC, Papakostas, G. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166:980–991.CrossRefGoogle ScholarPubMed
2.Shelton, RC, Tollefson, GD, Tohen, M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131–134.CrossRefGoogle ScholarPubMed
3.Tohen, M, Case, M, Trivedi, MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010;71(4):451–462.CrossRefGoogle Scholar